Abstract
Background: Metastatic Triple Negative Breast Cancers TNBCs become non-responsive to current chemotherapeutic treatment options. For decades Cisplatin is used in the treatment of different cancers and have shown clinical benefit against TNBCs. However, acquired resistance towards Cisplatin impedes its long-term benefits against TNBCs. Others and our studies have observed higher expression of AKT in TNBC cells and clinical samples, and dismal role of AKT towards drug response in other cancers is established.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
